Harmony Biosciences Holdings Inc — Quarterly Financial Statistics (NASDAQ:HRMY) | MetaTrader

Open full chart

Financials

Overview Relevé Statistics

Quarterly Annual

Cash from operating activities 75.56 M33.99 M79.33 M108.73 M126.15 M 348.2 M Cash from investing activities -7.19 M2.36 M-19.59 M-4.79 M-17.63 M -39.65 M Cash from financing activities -2.74 M-352 K-2.69 M-3 M-3.02 M -9.05 M Free cash flow 75.05 M33.86 M79.32 M108.66 M126.04 M 347.89 M

Nouvelles

Harmony Biosciences Holdings, Inc. (HRMY) Presents at 25th Annual Needham Virtual Healthcare Conference Transcript

Harmony Biosciences nomme Glenn Reicin au poste de directeur financier

BEAM's Q4 Loss Narrower Than Expected, Revenues Rise Y/Y

IOVA Beats on Q4 Earnings & Sales, Stock Soars on Pipeline Progress

RXRX Q4 Loss Narrower Than Expected, Revenues Increase Y/Y, Stock Up

Corcept's Q4 Earnings and Revenues Fall Short of Estimates

Repligen's Q4 Earnings Beat Estimates, Revenues Surge Y/Y

Apellis Q4 Loss Wider Than Expected, Revenues Decline Y/Y

UBS réduit l’objectif de cours d’Harmony Biosciences suite à une entrée anticipée des génériques de Wakix

UBS cuts Harmony Biosciences stock price target on earlier Wakix generic entry

Needham maintient son achat sur Harmony Biosciences Hldgs, mais abaisse l'objectif de cours à 44 $. | Benzinga France

Truist maintient sa recommandation Conserver sur Harmony Biosciences, objectif à 25$